0% do not beneÔ¨Åt from CEA.
Transfemoral CAS in symptomatic stenosis. A number of trials examined transfemoral CAS in management

of neurologically symptomatic patients with a greater
than 50% diameter stenosis. Several early trials in high
surgical risk patients such as Stenting and Angioplasty
with Protection in Patients at High Risk for Endarterectomy (SAPPHIRE), demonstrated overall equivalence of
transf